Compositions for treating CMT and related disorders

1. A method of improving nerve regeneration in a human subject suffering from amyotrophic lateral sclerosis, or a neuropathy selected from an idiopathic neuropathy, diabetic neuropathy, a toxic neuropathy, a neuropathy induced by a drug treatment, a neuropathy provoked by HIV, a neuropathy provoked by radiation, a neuropathy provoked by heavy metals, a neuropathy provoked by vitamin deficiency states, or a traumatic neuropathy, comprising administering to the human subject an amount of a composition effective to improve nerve regeneration; and wherein the composition comprises baclofen or a pharmaceutically acceptable salt thereof in an amount from 1 to 300 μg/kg of the human subject per day; D-sorbitol or a pharmaceutically acceptable salt thereof; and naltrexone or a pharmaceutically acceptable salt thereof in an amount from 1 to 100 μg/kg of the human subject per day.

2. The method of claim 1 , wherein the composition further comprises a pharmaceutically suitable excipient or carrier.

3. The method of claim 2 , wherein the composition is formulated with a drug eluting polymer, a biomolecule, a micelle or liposome-forming lipids or oil in water emulsions, or pegylated or solid nanoparticles or microparticles for oral or parenteral or intrathecal administration.

4. The method of claim 1 , wherein the subject suffers from a traumatic neuropathy arising from brain injury, spinal cord injury, or an injury to peripheral nerves.

5. The method of claim 1 , wherein the D-sorbitol or a pharmaceutically acceptable salt thereof is D-sorbitol.

6. The method of claim 1 , wherein the composition is formulated for oral administration.

7. The method of claim 6 , wherein the composition is a liquid formulation.

8. The method of claim 1 , wherein baclofen or a pharmaceutically acceptable salt thereof, D-sorbitol or a pharmaceutically acceptable salt thereof, and naltrexone or a pharmaceutically acceptable salt thereof are the sole active ingredients.

9. The method of claim 1 , comprising administering to the human subject baclofen or a pharmaceutically acceptable salt thereof in an amount from 10 to 200 μg/kg of the human subject per day and naltrexone or a pharmaceutically acceptable salt thereof in an amount from 1 to 50 μg/kg of the human subject per day.

10. The method of claim 1 , comprising administering to the human subject baclofen or a pharmaceutically acceptable salt thereof in an amount from 10 to 200 μg/kg of the human subject per day and naltrexone or a pharmaceutically acceptable salt thereof in an amount from 1 to 50 μg/kg of the human subject per day.

11. The method of claim 1 , comprising administering to the human subject baclofen or a pharmaceutically acceptable salt thereof in an amount from 60 μg to 18 mg per day and naltrexone or a pharmaceutically acceptable salt thereof in an amount from 60 μg to 6 mg per day.

12. The method of claim 1 , comprising administering to the human subject baclofen or a pharmaceutically acceptable salt thereof in an amount from 60 μg to 12 mg per day and naltrexone or a pharmaceutically acceptable salt thereof in an amount from 60 μg to 3 mg per day.

13. The method of claim 10 , wherein baclofen or a pharmaceutically acceptable salt thereof, D-sorbitol or a pharmaceutically acceptable salt thereof, and naltrexone or a pharmaceutically acceptable salt thereof are administered orally to the human subject.

14. The method of claim 10 , wherein baclofen or a pharmaceutically acceptable salt thereof, D-sorbitol or a pharmaceutically acceptable salt thereof, and naltrexone or a pharmaceutically acceptable salt thereof are administered separately to the human subject.

15. The method of claim 13 , wherein baclofen or a pharmaceutically acceptable salt thereof, D-sorbitol or a pharmaceutically acceptable salt thereof, and naltrexone or a pharmaceutically acceptable salt thereof are formulated in a liquid formulation.

16. The method of claim 15 , wherein baclofen or a pharmaceutically acceptable salt thereof, D-sorbitol or a pharmaceutically acceptable salt thereof, and naltrexone or a pharmaceutically acceptable salt thereof are administered to the human subject in divided doses.

17. The method of claim 15 , wherein baclofen or a pharmaceutically acceptable salt thereof, D-sorbitol or a pharmaceutically acceptable salt thereof, and naltrexone or a pharmaceutically acceptable salt thereof are administered to the human subject in divided doses two times daily.